Sharven Taghavi1, Senthil N Jayarajan1, Yuka Furuya2, Eugene Komaroff3, Akira Shiose4, Eros Leotta4, Kazuhiro Hisamoto4, Namrata Patel2, Francis Cordova2, Gerard Criner2, T Sloane Guy4, Yoshiya Toyoda5. 1. Department of Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania. 2. Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania. 3. Department of Public Health, Temple University, Philadelphia, Pennsylvania. 4. Section of Cardiothoracic Surgery, Temple University, Philadelphia, Pennsylvania. 5. Section of Cardiothoracic Surgery, Temple University, Philadelphia, Pennsylvania. Electronic address: yoshiya.toyoda@tuhs.temple.edu.
Abstract
BACKGROUND: The short-term and long-term effect of using ABO compatible donors in the era of lung allocation score is unknown. This study determined if carefully selected ABO compatible donors could be used in double lung transplantation (DLT) with good outcomes. METHODS: The United Network for Organ Sharing database was retrospectively reviewed for adult DLT from May 2005 to December 2011. RESULTS: Of 6,655 double lung transplants, 493 (7.4%) were with ABO compatible donors and 6,162 (92.6%) were with ABO identical donors. In multivariate analysis, use of ABO compatible donors was not associated with mortality at 30 days (HR, 1.16; 95% CI, 0.76 to 1.79, p = 0.49), 1 year (HR, 1.10; 95% CI, 0.86 to 1.42, p = 0.46), and 5 years (HR, 1.06; 95% CI, 0.83 to 1.34, p = 0.65). Variables associated with mortality at 5 years were donor female sex, donor age 60 years or greater, prolonged ischemic time, increasing recipient creatinine, recipient age, race mismatch, and mechanical ventilation or extracorporeal membrane oxygenation as a bridge to transplantation. Length of stay was longer in the ABO compatible group (30.9 vs 25.9 days, p = 0.001). Acute rejection episodes on index hospitalization (8.8 vs. 8.9%, p = 1.00), peak posttransplant forced expiratory volume in 1 second (FEV1) (82.7 vs 79.7%, p = 0.053), and decrement in FEV1 over time were not different (p = 0.13). Freedom from bronchiolitis obliterans syndrome was similar (1,475 vs 1,454 days, p = 0.17). CONCLUSIONS: The use of ABO compatible donors in the era of lung allocation score was not associated with short-term or long-term mortality and resulted in equivalent posttransplant lung function. A DLT with carefully selected ABO compatible donors can result in excellent outcomes.
BACKGROUND: The short-term and long-term effect of using ABO compatible donors in the era of lung allocation score is unknown. This study determined if carefully selected ABO compatible donors could be used in double lung transplantation (DLT) with good outcomes. METHODS: The United Network for Organ Sharing database was retrospectively reviewed for adult DLT from May 2005 to December 2011. RESULTS: Of 6,655 double lung transplants, 493 (7.4%) were with ABO compatible donors and 6,162 (92.6%) were with ABO identical donors. In multivariate analysis, use of ABO compatible donors was not associated with mortality at 30 days (HR, 1.16; 95% CI, 0.76 to 1.79, p = 0.49), 1 year (HR, 1.10; 95% CI, 0.86 to 1.42, p = 0.46), and 5 years (HR, 1.06; 95% CI, 0.83 to 1.34, p = 0.65). Variables associated with mortality at 5 years were donor female sex, donor age 60 years or greater, prolonged ischemic time, increasing recipient creatinine, recipient age, race mismatch, and mechanical ventilation or extracorporeal membrane oxygenation as a bridge to transplantation. Length of stay was longer in the ABO compatible group (30.9 vs 25.9 days, p = 0.001). Acute rejection episodes on index hospitalization (8.8 vs. 8.9%, p = 1.00), peak posttransplant forced expiratory volume in 1 second (FEV1) (82.7 vs 79.7%, p = 0.053), and decrement in FEV1 over time were not different (p = 0.13). Freedom from bronchiolitis obliterans syndrome was similar (1,475 vs 1,454 days, p = 0.17). CONCLUSIONS: The use of ABO compatible donors in the era of lung allocation score was not associated with short-term or long-term mortality and resulted in equivalent posttransplant lung function. A DLT with carefully selected ABO compatible donors can result in excellent outcomes.
Authors: Yaron D Barac; Mike S Mulvihill; Morgan L Cox; Muath Bishawi; Jacob Klapper; John Haney; Mani Daneshmand; Matthew G Hartwig Journal: J Heart Lung Transplant Date: 2018-09-25 Impact factor: 10.247
Authors: Sharven Taghavi; Vishnu Ambur; Senthil Jayarajan; John Gaughan; Yoshiya Toyoda; Elizabeth Dauer; Lars Ola Sjoholm; Abhijit Pathak; Thomas Santora; Amy J Goldberg Journal: Ann Med Surg (Lond) Date: 2015-12-23